About this article Cite this article Yen, K., Hughes, E., Savic, R
Mautner VF, Friedrich RE, von Deimling A, Hagel C, Korf B, Knofel MT, et al
Way Forward 1
Study findings The study leveraged a total of 114 adult non-diabetic participants (randomized 1:1:1 to tirzepatide [n=37], liraglutide [n=38], or placebo [n=39])
In the past year, many telehealth and digital health companies have jumped into the market, offering prescriptions for GLP-1s as part of an existing weight loss or chronic condition management program, or creating a new service line targeting obesity care
For example, in the STEP 4 trial, participants who stayed on semaglutide for 68 weeks lost an additional 7.9% of their body weight